NEW YORK and PETACH TIKVAH, Israel, Nov. 5, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial results on Thursday, November 13, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. Eastern Time to discuss the third quarter financial results. Dial-in and replay information are provided below.
Conference Call & Webcast | |
Thursday, November 13, 2014 at 8:30 a.m. EST/5:30 a.m. PST | |
Domestic: | 888-438-5525 |
International: | 719-457-2083 |
Conference ID: | 5950362 |
Webcast: | |
Replays Available through November 27, 2014 | |
Domestic: | 877-870-5176 |
International: | 858-384-5517 |
Conference ID: | 5950362 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
SOURCE BrainStorm Cell Therapeutics Inc.
